Amaranth

Amaranth

SCHEMBL473254

O=S(=O)(O)c1ccc2c(/N=N/c3ccc(S(=O)(=O)O)c4ccccc34)c(O)c(S(=O)(=O)O)cc2c1.[NaH].[NaH].[NaH].[NaH].[NaH].[NaH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.98
MEN1 O00255 1/20 0.98
KMT2A Q03164 1/20 0.98
TDP1 Q9NUW8 1/20 0.98
CYP1A2 P05177 6/20 0.78
ALDH1A1 P00352 4/20 0.78
HIF1A Q16665 3/20 0.78
CYP2C9 P11712 2/20 0.57
TSHR P16473 1/20 0.57
PTPRA P18433 1/20 0.57
PTPRB P23467 1/20 0.57
CYP2C19 P33261 1/20 0.57
RAPGEF4 Q8WZA2 1/20 0.57
HSD17B10 Q99714 1/20 0.57
CTRB1 P17538 1/20 0.56
ENPP2 Q13822 4/20 0.56
MAPK1 P28482 2/20 0.53
DNASE1L3 Q13609 1/20 0.53
MPL P40238 3/20 0.48
CTRC Q99895 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amaranth SCHEMBL27515187 1.00 THRB (0.98) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL185412 1.00 THRB (0.98) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL9577797 1.00 THRB (0.98) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL4807654 1.00 THRB (0.98) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL1461501 0.99 THRB (0.96) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL29371627 0.99 THRB (1.00) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL108344 0.99 THRB (1.00) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL31222692 0.99 THRB (1.00) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL344622 0.99 THRB (1.00) THRBMEN1KMT2ATDP1CYP1A2
Amaranth SCHEMBL185414 0.99 THRB (1.00) THRBMEN1KMT2ATDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596264-B2 Limiting, reducing, or eliminating the transfer or migration of a cosmetic, dermatological, hygienic or pharmaceutical composition L'OREAL SA (FR) 2003-07-22 US claimed
US-20020028226-A1 Composition especially in the form of emulsion, gel or aqueous solution, including a crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90% L'OREAL 2002-03-07 US claimed
US-6287543-B1 CONTAINING CROSSLINKED, NEUTRALIZED POLY(2-ACRYLAMIDO-2-METHYLPROPANESULFONIC ACID) L'OREAL (FR) 2001-09-11 US claimed
CN-114615912-B System for picking up and applying a cosmetic composition 欧莱雅 2024-03-08 CN disclosed
CN-109939043-B Alcohol extract of aerial parts of villus of wound, method for obtaining same, and cosmetic or pharmaceutical composition containing same 香奈儿香水美妆品公司 2023-01-20 CN disclosed
CN-114615912-A System for picking up and applying a cosmetic composition 欧莱雅 2022-06-10 CN disclosed
US-11331264-B2 Fermented extract of aerial parts of bitter orange CHANEL PARFUMS BEAUTE (FR) 2022-05-17 US disclosed
US-11304891-B2 Process for extracting plants CHANEL PARFUMS BEAUTE (FR) 2022-04-19 US disclosed
CN-114080171-A Method for forming an applicator for applying a cosmetic composition 欧莱雅 2022-02-22 CN disclosed
CN-114025640-A Device for picking up and applying a cosmetic product 欧莱雅 2022-02-08 CN disclosed
CN-105848725-B Transfer device for making up keratin materials 欧莱雅 2021-11-12 CN disclosed
US-20020028226-A1 Composition especially in the form of emulsion, gel or aqueous solution, including a crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90% L'OREAL 2002-03-07 US disclosed
US-6287543-B1 CONTAINING CROSSLINKED, NEUTRALIZED POLY(2-ACRYLAMIDO-2-METHYLPROPANESULFONIC ACID) L'OREAL (FR) 2001-09-11 US disclosed
CN-1247055-A Face-care compsns. containing pigment and anti-sweat agent, and application of same composns. OREAL (FR) 2000-03-15 CN disclosed
CN-1246327-A Cosmetic composite containing pigment, anti-sweat agent and partial cross-linked solid elastic organic polyorganosiloxane and use of the composite OREAL (FR) 2000-03-08 CN disclosed
CN-1235014-A Use of 1,2-pentanediol in cosmetic or dermatological composition containing aqueous dispersion of film-forming polymer particles, and cosmetic or dermatological composition comprising these constituen OREAL (FR) 1999-11-17 CN disclosed
US-5972354-A COSMETIC COMPOSITION, CAPABLE OF BEING APPLIED TO THE SKIN, THE SEMIMUCOSAE AND/OR THE MUCOSAE; INCLUDES AN AQUEOUS DISPERSION OF PARTICLES OF FILM-FORMING POLYMER AND CAN BE EMPLOYED AS A MAKE-UP PRODUCT L'OREAL (FR) 1999-10-26 US disclosed
US-5958387-A COPOLYMER OF SILOXANE AND HYDROLYZED OR UNHYDROLYZED PROTEIN, OR DIMETHICONE COPOLYOLS AND THEIR DERIVATIVES SOLUBILIZED IN AQUEOUS PHASE L'OREAL (FR) 1999-09-28 US disclosed
US-5626853-A Aqueous make-up gel containing organopolysiloxane L'OREAL (FR) 1997-05-06 US disclosed
US-5593680-A COSMETIC PROCESS COMPRISING APPLYING COMPOSITION TO SKIN; GELLING AGENT IS WATER-SOLUBLE POLYMER, POLYMER PROVIDING COLLOIDAL SOLUTION IN WATER, COLLOIDAL SILICATE OR HYDROPHILIC SILICA GEL L'OREAL (FR) 1997-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028226-A1 Composition especially in the form of emulsion, gel or aqueous solution, including a crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90% CUTA, ACR, PARN THRB 4808/4885MEN1 2389/4885KMT2A 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.